FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1965 May 1, 2008 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Cunningham, D. PubMed Citation

To the Editor: Cunningham et al. (Jan. 3 issue)¹ state that capecitabine and oxaliplatin are equivalent to fluorouracil and cisplatin in esophagogastric cancer. One disadvantage of their study is that patients with squamous-cell carcinoma were not excluded. Furthermore, it seems that combinations of capecitabine and oxaliplatin are not less toxic or more effective but their cost is 5 to 10 times that of therapy with epirubicin, cisplatin, and fluorouracil (ECF). Moreover, peripheral neuropathy occurs more frequently with oxaliplatin.^2,3 We therefore see no better profile for capecitabine and oxaliplatin in patients with advanced esophagogastric cancer.

Edwin Bölke, M.D.
Matthias Peiper, M.D.
. . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.